Open Access
J Oral Med Oral Surg
Volume 29, Number 4, 2023
Article Number 41
Number of page(s) 10
Published online 02 February 2024
  1. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 2009;15:1395–1401. [CrossRef] [PubMed] [Google Scholar]
  2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-associated infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010;50:1091–1100. [CrossRef] [PubMed] [Google Scholar]
  3. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-associated infection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50:1101–1111. [CrossRef] [PubMed] [Google Scholar]
  4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634–653. [CrossRef] [PubMed] [Google Scholar]
  5. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK Jr, Walsh TJ. Zygomycosis in neonates: an uncommon, but life-threatening infection. Am J Perinatol 2009;26:565–573. [CrossRef] [PubMed] [Google Scholar]
  6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513. [Google Scholar]
  7. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungai 2021;7:298. [CrossRef] [Google Scholar]
  8. Serris A, Danion F, Lanternier F. Disease entities in mucormycosis. J Fungi (Basel) 2019;5:23. [CrossRef] [Google Scholar]
  9. Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021;64:1028–1037. [CrossRef] [PubMed] [Google Scholar]
  10. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect 2016;22:811–e1. [Google Scholar]
  11. Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother 2019;74:3315–3327. [CrossRef] [PubMed] [Google Scholar]
  12. Esteak, Tareq, et al. Mucormycosis in Different Clinical Settings: A Case Series. Cureus 2022;14:4. [Google Scholar]
  13. Iqtadar, Somia, et al. Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes–a case series from Lahore, Pakistan. Therapeutic advances in infectious disease 2022;9:20499361221097417. [Google Scholar]
  14. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54:23–34. [Google Scholar]
  15. Bhandari J, Thada PK, Nagalli S. Rhinocerebral mucormycosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: [Google Scholar]
  16. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012;54:S16– S22. [CrossRef] [PubMed] [Google Scholar]
  17. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556–569. [CrossRef] [PubMed] [Google Scholar]
  18. Binder U, Maurer E, Lass-Flörl C. Mucormycosis—from the pathogens to the disease. Clin Microbiol Infect 2014;20:60–66. [CrossRef] [PubMed] [Google Scholar]
  19. Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012;54:S55– S60. [CrossRef] [PubMed] [Google Scholar]
  20. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–856. [CrossRef] [PubMed] [Google Scholar]
  21. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24: 247–280. [CrossRef] [PubMed] [Google Scholar]
  22. Schuetz AN, Walsh TJ. Importance of fungal histopathology in immunocompromised pediatric patients: it's not just “Aspergillus” anymore. Am J Clin Pathol 2015;144:185–187. [CrossRef] [PubMed] [Google Scholar]
  23. Otto WR, Pahud BA, Yin DE. Pediatric mucormycosis: a 10-year systematic review of reported cases and review of the literature. J Pediatr Infect Dis Soc 2019;8:342–350. [CrossRef] [Google Scholar]
  24. Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004;45:1351–1360. [CrossRef] [PubMed] [Google Scholar]
  25. Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012;50: 611–618. [CrossRef] [PubMed] [Google Scholar]
  26. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002;49:7–10. [CrossRef] [Google Scholar]
  27. Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012;50: 611–618. [CrossRef] [PubMed] [Google Scholar]
  28. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503–509. [CrossRef] [PubMed] [Google Scholar]
  29. Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance: focus on mucormycosis. Mycoses 2014;57:240–246. [CrossRef] [PubMed] [Google Scholar]
  30. Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010; 48: 511–517. [CrossRef] [PubMed] [Google Scholar]
  31. Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 2009;15:87–92. [CrossRef] [PubMed] [Google Scholar]
  32. Chayakulkeeree M, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215–229. [CrossRef] [PubMed] [Google Scholar]
  33. Manesh A, John AO, Mathew B, Varghese L, Rupa V, Zachariah A, Varghese GM. Posaconazole: an emerging therapeutic option for invasive rhino‐orbito‐cerebral mucormycosis. Mycoses 2016;59: 765–772. [CrossRef] [PubMed] [Google Scholar]
  34. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185–192. [CrossRef] [PubMed] [Google Scholar]
  35. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61–e65. [CrossRef] [PubMed] [Google Scholar]
  36. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126–133. [CrossRef] [PubMed] [Google Scholar]
  37. Chen L, Krekels EH, Verweij P, Buil JB, Knibbe CA, Brüggemann RJ. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 2020;80:671–695. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.